Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

Background: As the use of immune checkpoint inhibitors in postoperative adjuvant chemotherapy for patients with programmed death-ligand 1 (PD-L1)-expressing lung cancer has been increasing, it is ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.